newsfilter
← Latest News
PR Newswire·

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of...